Tim Anderson
Stock Analyst at B of A Securities
(3.44)
# 426
Out of 5,152 analysts
50
Total ratings
53.85%
Success rate
5.55%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Tim Anderson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JNJ Johnson & Johnson | Maintains: Neutral | $220 → $221 | $239.63 | -7.77% | 10 | Jan 22, 2026 | |
| LLY Eli Lilly and Company | Maintains: Buy | $1,286 → $1,268 | $983.26 | +28.96% | 2 | Dec 15, 2025 | |
| MRK Merck & Co. | Maintains: Buy | $105 → $120 | $116.07 | +3.39% | 5 | Dec 15, 2025 | |
| BMY Bristol-Myers Squibb Company | Upgrades: Buy | $52 → $61 | $60.74 | +0.43% | 2 | Dec 15, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Underperform | $543 → $627 | $764.93 | -18.03% | 3 | Oct 29, 2025 | |
| PFE Pfizer | Maintains: Neutral | $28 → $30 | $26.61 | +12.74% | 3 | Oct 3, 2025 | |
| AMGN Amgen | Maintains: Underperform | $261 → $272 | $367.60 | -26.01% | 6 | Sep 26, 2025 | |
| APGE Apogee Therapeutics | Maintains: Buy | $78 → $87 | $70.92 | +22.67% | 1 | Aug 28, 2025 | |
| AARD Aardvark Therapeutics | Maintains: Buy | $26 → $25 | $5.74 | +335.54% | 3 | Aug 28, 2025 | |
| ABBV AbbVie | Maintains: Neutral | $200 → $204 | $232.35 | -12.20% | 7 | Apr 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $116 → $126 | $145.14 | -13.19% | 3 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $41 → $34 | $53.83 | -36.84% | 2 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $178 | $188.08 | -5.36% | 1 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $161.01 | - | 1 | May 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $197.52 | - | 1 | Sep 22, 2017 |
Johnson & Johnson
Jan 22, 2026
Maintains: Neutral
Price Target: $220 → $221
Current: $239.63
Upside: -7.77%
Eli Lilly and Company
Dec 15, 2025
Maintains: Buy
Price Target: $1,286 → $1,268
Current: $983.26
Upside: +28.96%
Merck & Co.
Dec 15, 2025
Maintains: Buy
Price Target: $105 → $120
Current: $116.07
Upside: +3.39%
Bristol-Myers Squibb Company
Dec 15, 2025
Upgrades: Buy
Price Target: $52 → $61
Current: $60.74
Upside: +0.43%
Regeneron Pharmaceuticals
Oct 29, 2025
Maintains: Underperform
Price Target: $543 → $627
Current: $764.93
Upside: -18.03%
Pfizer
Oct 3, 2025
Maintains: Neutral
Price Target: $28 → $30
Current: $26.61
Upside: +12.74%
Amgen
Sep 26, 2025
Maintains: Underperform
Price Target: $261 → $272
Current: $367.60
Upside: -26.01%
Apogee Therapeutics
Aug 28, 2025
Maintains: Buy
Price Target: $78 → $87
Current: $70.92
Upside: +22.67%
Aardvark Therapeutics
Aug 28, 2025
Maintains: Buy
Price Target: $26 → $25
Current: $5.74
Upside: +335.54%
AbbVie
Apr 28, 2025
Maintains: Neutral
Price Target: $200 → $204
Current: $232.35
Upside: -12.20%
Mar 5, 2025
Maintains: Buy
Price Target: $116 → $126
Current: $145.14
Upside: -13.19%
Feb 11, 2025
Maintains: Underperform
Price Target: $41 → $34
Current: $53.83
Upside: -36.84%
Dec 10, 2024
Reinstates: Neutral
Price Target: $178
Current: $188.08
Upside: -5.36%
May 9, 2022
Downgrades: Peer Perform
Price Target: n/a
Current: $161.01
Upside: -
Sep 22, 2017
Upgrades: Outperform
Price Target: n/a
Current: $197.52
Upside: -